CN115433123A - 一种氯雷他定中间体的制备方法 - Google Patents
一种氯雷他定中间体的制备方法 Download PDFInfo
- Publication number
- CN115433123A CN115433123A CN202211223091.6A CN202211223091A CN115433123A CN 115433123 A CN115433123 A CN 115433123A CN 202211223091 A CN202211223091 A CN 202211223091A CN 115433123 A CN115433123 A CN 115433123A
- Authority
- CN
- China
- Prior art keywords
- compound
- loratadine
- preparing
- molar ratio
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 229960003088 loratadine Drugs 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 238000006243 chemical reaction Methods 0.000 claims abstract description 18
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims abstract description 16
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims abstract description 15
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims abstract description 14
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000003960 organic solvent Substances 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000003999 initiator Substances 0.000 claims abstract description 8
- 150000003557 thiazoles Chemical class 0.000 claims abstract description 8
- SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 claims abstract description 7
- WBXZCDIZXWDPBL-UHFFFAOYSA-N 3-methylpyridine-2-carbonitrile Chemical compound CC1=CC=CN=C1C#N WBXZCDIZXWDPBL-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000003054 catalyst Substances 0.000 claims abstract description 7
- 150000007524 organic acids Chemical class 0.000 claims abstract description 7
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 4
- 230000009471 action Effects 0.000 claims abstract description 3
- 238000005893 bromination reaction Methods 0.000 claims abstract description 3
- 150000003254 radicals Chemical class 0.000 claims abstract description 3
- 238000006722 reduction reaction Methods 0.000 claims abstract description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 8
- 230000035484 reaction time Effects 0.000 claims description 8
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 3
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 abstract description 6
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract description 3
- 238000010511 deprotection reaction Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000000543 intermediate Substances 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- JPCGKKFEDUHGDF-UHFFFAOYSA-N 3-[2-(3-chlorophenyl)ethyl]pyridine-2-carbonitrile Chemical compound ClC1=CC=CC(CCC=2C(=NC=CC=2)C#N)=C1 JPCGKKFEDUHGDF-UHFFFAOYSA-N 0.000 description 5
- 239000007787 solid Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- -1 3- (2- (3-chlorophenyl) -2-oxoethyl) pyridinecarbonitrile Chemical compound 0.000 description 2
- BSSLVCQAYWTRRC-UHFFFAOYSA-N 3-(bromomethyl)pyridine-2-carbonitrile Chemical compound BrCC1=CC=CN=C1C#N BSSLVCQAYWTRRC-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000004096 non-sedating histamine H1 antagonist Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyridine Compounds (AREA)
Abstract
本发明公开了一种氯雷他定中间体的制备方法,包括以下步骤:(1)将化合物II 2‑氰基‑3‑甲基吡啶溶解至有机溶剂中,再加入N‑溴代琥珀酰亚胺和引发剂,经过自由基溴化反应得到化合物III;(2)在氮气保护下,将化合物III与间氯苯甲醛溶解在有机溶剂中,加入噻唑盐和催化剂,反应得到化合物IV;(3)将化合物IV溶解于有机酸中,在三甲基硅烷作用进行还原反应,得到化合物I。本发明以2‑氰基‑3‑甲基吡啶作为起始原料,通过四步反应得到目标化合物,避免经常使用的正丁基锂等危险试剂,反应条件温和,并且不需要进行对氰基保护再脱保护的过程,具备工业前景。
Description
技术领域
本发明属于医药中间体有机合成技术领域,具体涉及一种氯雷他定中间体的制备方法。
背景技术
氯雷他定的化学名称为4-(8-氯-5,6-二氢-11H-苯并[5,6]-环庚并[1,2-b]吡啶-11-烯基)-1-哌啶羧酸乙酯,其作为第二代抗组胺药的代表,可竞争性抑制组胺H1受体以及组胺所引起的过敏症状,且无明显的抗中枢和胆碱抑制作用,临床疗效好。
目前有关氯雷他定的合成方法有很多种,其中多种合成路线均涉及一个共用中间体3-(3-氯苯乙基)-2-氰基吡啶(化合物I)。
例如,路线一:
路线二:
如上所示,化合物I是合成氯雷他定的重要中间体,简化该中间体的合成对于氯雷他定的合成具有重大的意义。
发明内容
本发明所要解决的技术问题是提供一种氯雷他定中间体的制备方法,该氯雷他定中间体为3-(3-氯苯乙基)-2-氰基吡啶,该方法使用的原料易得,环境友好,反应收率高,操作简便,易于工业化生产。
本发明的一种氯雷他定中间体的制备方法,其结构式如式(I)所示,包括以下步骤:
(1)将化合物II 2-氰基-3-甲基吡啶溶解至有机溶剂中,再加入N-溴代琥珀酰亚胺和引发剂,经过自由基溴化反应得到化合物III;
(2)在氮气保护下,将化合物III与间氯苯甲醛溶解在有机溶剂中,加入噻唑盐和催化剂,反应得到化合物IV;
(3)将化合物IV溶解于有机酸中,在三甲基硅烷作用进行还原反应,得到化合物I;
合成路线如下:
进一步的,步骤(1)中所述的引发剂为AIBN或BPO,所述化合物II与引发剂摩尔比为1:0.05~0.12。
进一步的,步骤(1)中所述化合物II与引发剂摩尔比为1:0.1。
进一步的,步骤(1)中所述化合物II与N-溴代琥珀酰亚胺的摩尔比为1:1~5。
进一步的,步骤(1)中所述化合物II与N-溴代琥珀酰亚胺的摩尔比为1:3。
进一步的,步骤(1)中所述有机溶剂为1,2-二氯乙烷,其用量与化合物II的质量比为1:1-10。
进一步的,步骤(1)中所述有机溶剂与化合物II的体积比为1:4-6。
进一步的,步骤(1)中所述反应温度为10-120℃,反应时间为2-30小时。
进一步的,步骤(1)中所述反应温度为30-100℃,反应时间为10-24小时。
进一步的,步骤(2)中所述的催化剂为DBU,其中化合物III与催化剂的摩尔比1:0.5~1.2,优选1:1。
进一步的,步骤(2)中所述的化合物III与间氯苯甲醛的摩尔比为1:0.8~1.6。
进一步的,步骤(2)中所述的化合物III与间氯苯甲醛的摩尔比为1:1.2。
进一步的,步骤(2)中所述的有机溶剂为乙腈,乙腈用量为化合物II质量的1-10倍,优选4-6倍。
进一步的,步骤(2)的反应温度为10-100℃,反应时间为0.5-3小时。
进一步的,步骤(2)的反应温度为20-40℃,反应时间为1-2小时。
进一步的,步骤(3)中所述的所述有机酸为三氟乙酸,有机酸用量为化合物IV质量的1-6倍,优选3-5倍。
进一步的,步骤(3)中所述的化合物IV与三甲基硅烷的摩尔比1:1.2~2,步骤(3)的反应温度为10-100℃,反应时间为2-30小时。
进一步的,步骤(3)中所述的化合物IV与三甲基硅烷的摩尔比1:1.5,步骤(3)的反应温度为20-40℃,反应时间为10-24小时。
本申请以化合物II 2-氰基-3-甲基吡啶作为起始原料,通过四步反应得到目标化合物I。这一合成路线避免了经常使用的正丁基锂等危险试剂,并且不需要进行对氰基保护再脱保护的过程,具备非常有价值的工业前景。
有益效果:
(1)本发明提供了一种氯雷他定中间体3-(3-氯苯乙基)-2-氰基吡啶的制备方法,以常见的2-氰基-3-甲基吡啶为起始原料,经过三步反应,以串联的方式合成,工艺操作简单,反应收率较高。
(2)本发明的制备方法反应条件温和,避免使用正丁基锂等危险试剂。
(3)本发明的制备方法中不需要进行对氰基保护再脱保护的过程,路线简洁高效,具备非常有价值的工业前景。
具体实施方式
下面进一步说明本发明的实施例。
实施例1
3-(溴甲基)-2-吡啶腈(化合物III)的制备
将2-氰基-3-甲基吡啶(20g,169mmol)加入1L的圆底烧瓶中,加入1,2-二氯乙烷(200mL),升温至回流,加入AIBN(2.78g,16.9mmol),分批加入N-溴代琥珀酰亚胺(36.17g,203mmol),回流反应24小时。冷却至0℃,析出大量固体,过滤,收集滤液减压浓缩,得到3-(溴甲基)-2-吡啶腈(化合物III)(30.25g,黄色油状物,纯度91%),收率为82.66%。
1HNMR(400MHz,CDCl3)δ(ppm):8.65-8.64(m,1H),7.92(d,J=8.0Hz,1H),7.54(dd,J=7.9,4.8Hz,1H),4.64(s,2H).
13CNMR(100MHz,CDCl3)δ(ppm):150.7,138.5,138.3,133.3,127.2,115.4,27.0.
实施例2
3-(2-(3-氯苯基)-2-氧代乙基)吡啶甲腈(化合物IV)的制备
氮气保护下,将化合物III(30g,138mmol,纯度91%)加入1L的圆底烧瓶中,加入乙腈(200mL),依次加入间氯苯甲醛(23.6g,169mmol)、噻唑盐(28.9g,120mmol)和DBU(18.2g,120mmol),室温反应1小时,过滤,滤液减压浓缩,经柱层析纯化得到3-(2-(3-氯苯基)-2-氧代乙基)吡啶甲腈(化合物IV)(20g,黄色固体,纯度90%),收率为65.54%。
实施例3
3-(3-氯苯乙基)-2-氰基吡啶(化合物I)的制备
将化合物IV(20g,81mmol,纯度90%)加入反应釜中,加入三氟乙酸(80mL),缓慢加入三甲基硅烷(9g,120mmol)的三氟乙酸溶液(20mL),室温搅拌24小时,反应液用水淬灭,正己烷萃取3次,合并有机相,无水硫酸钠干燥,过滤,减压浓缩,残余物经石油醚重结晶得到3-(3-氯苯乙基)-2-氰基吡啶(化合物I)(15g,黄白色固体,纯度95%),收率为80%。
1HNMR(400MHz,CDCl3)δ(ppm):8.54(dd,J=4.8,1.2Hz,1H),7.54(dd,J=4.8Hz,1.2Hz,1H),7.40(dd,J=7.8,4.8Hz,1H),7.20(m,2H),7.13(t,J=1.8Hz,1H),7.02(dt,J=7.2,1.2Hz,1H),3.13(t,J=7.2Hz,2H),2.94(t,J=7.2Hz,2H).
以上对本发明的具体实施例进行了详细描述,但其只是作为范例,本发明并不限制于以上描述具体实施例。对于本领域技术人员而言,任何对本发明进行的等同修改和替代也都在本发明的范畴之中。因此,在不脱离本发明的精神和范围下所作的均等变换和修改,都涵盖在本发明范围内。
Claims (10)
2.根据权利要求1所述的氯雷他定中间体的制备方法,其特征在于,步骤(1)中所述的引发剂为AIBN或BPO,所述化合物II与引发剂摩尔比为1:0.05~0.12。
3.根据权利要求1所述的氯雷他定中间体的制备方法,其特征在于,步骤(1)中所述化合物II与N-溴代琥珀酰亚胺的摩尔比为1:1~5。
4.根据权利要求1所述的氯雷他定中间体的制备方法,其特征在于,步骤(1)中所述有机溶剂为1,2-二氯乙烷,其用量与化合物II的质量比为1:1-10。
6.根据权利要求1所述的氯雷他定中间体的制备方法,其特征在于,步骤(2)中所述的催化剂为DBU,其中化合物III与催化剂的摩尔比1:0.5~1.2。
7.根据权利要求1所述的氯雷他定中间体的制备方法,其特征在于,进一步的,步骤(2)中所述的化合物III与间氯苯甲醛的摩尔比为1:0.8~1.6。
8.根据权利要求1所述的氯雷他定中间体的制备方法,其特征在于,步骤(2)中所述的有机溶剂为乙腈,乙腈用量为化合物II质量的1-10倍;步骤(2)的反应温度为10-100℃,反应时间为0.5-3小时。
9.根据权利要求1所述的氯雷他定中间体的制备方法,其特征在于,步骤(3)中所述的所述有机酸为三氟乙酸,有机酸用量为化合物IV质量的1-6倍。
10.根据权利要求1所述的氯雷他定中间体的制备方法,其特征在于,步骤(3)中所述的化合物IV与三甲基硅烷的摩尔比1:1.2~2,步骤(3)的反应温度为10-100℃,反应时间为2-30小时。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211223091.6A CN115433123B (zh) | 2022-10-08 | 一种氯雷他定中间体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211223091.6A CN115433123B (zh) | 2022-10-08 | 一种氯雷他定中间体的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115433123A true CN115433123A (zh) | 2022-12-06 |
CN115433123B CN115433123B (zh) | 2024-06-28 |
Family
ID=
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5422351A (en) * | 1990-06-22 | 1995-06-06 | Schering Corporation | Bis-benzo or benzopyrido cyclohepta piperidene, piperidylidene and piperazine compounds, compositions and methods of use |
CN101830784A (zh) * | 2010-05-18 | 2010-09-15 | 华东理工大学 | 制备α-芳基酮类化合物的方法 |
CN106588761A (zh) * | 2016-11-22 | 2017-04-26 | 宜昌东阳光药业股份有限公司 | 一种氯雷他定中间体的合成方法 |
CN107400083A (zh) * | 2017-08-28 | 2017-11-28 | 四川大学 | 一种3‑[2‑(3‑氯苯基)乙基]‑2‑吡啶甲腈的制备方法 |
CN114874081A (zh) * | 2022-05-08 | 2022-08-09 | 中国人民解放军海军军医大学 | 一种绿色高效α-官能化酮的制备方法 |
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5422351A (en) * | 1990-06-22 | 1995-06-06 | Schering Corporation | Bis-benzo or benzopyrido cyclohepta piperidene, piperidylidene and piperazine compounds, compositions and methods of use |
CN101830784A (zh) * | 2010-05-18 | 2010-09-15 | 华东理工大学 | 制备α-芳基酮类化合物的方法 |
CN106588761A (zh) * | 2016-11-22 | 2017-04-26 | 宜昌东阳光药业股份有限公司 | 一种氯雷他定中间体的合成方法 |
CN107400083A (zh) * | 2017-08-28 | 2017-11-28 | 四川大学 | 一种3‑[2‑(3‑氯苯基)乙基]‑2‑吡啶甲腈的制备方法 |
CN114874081A (zh) * | 2022-05-08 | 2022-08-09 | 中国人民解放军海军军医大学 | 一种绿色高效α-官能化酮的制备方法 |
Non-Patent Citations (1)
Title |
---|
LU LIN, 等: "The NHCs-mediated cross-coupling of aromatic aldehydes with benzyl halides: synthesis of a-aryl ketones", 《TETRAHEDRON LETTERS》, vol. 51, pages 3571, XP027067209, DOI: 10.1016/j.tetlet.2010.05.003 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013047248A (ja) | インテグラーゼ阻害剤を調製するためのプロセスおよび中間体 | |
NO342589B1 (no) | Fremgangsmåte for fremstilling av tetrazol-metansulfonsyresalter og ny forbindelse som anvendes i denne | |
WO2015124764A1 (en) | Synthesis process of dabigatran etexilate mesylate, intermediates of the process and novel polymorph of dabigatran etexilate | |
EP1700855B1 (en) | A process for the preparation of tazarotene | |
JP3930736B2 (ja) | ピリジンメタノール化合物の製造方法 | |
CN115433123B (zh) | 一种氯雷他定中间体的制备方法 | |
CN105358529A (zh) | 一种合成阿哌沙班重要中间体的新方法 | |
CN115433123A (zh) | 一种氯雷他定中间体的制备方法 | |
JP6096465B2 (ja) | ペランパネルの中間体である2−アルコキシ−5−(ピリジン−2−イル)ピリジンの調製方法 | |
CN109134351B (zh) | S-3-(4-氨基苯基)哌啶的合成方法 | |
CN111620788B (zh) | 一种制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法 | |
CA2465686C (en) | Process for the preparation of 4-(8-chloro-5,6-dihydro-11h-benzo(5,6)-cyclohepta-(1,2b)-pyridin-11-ylidene)-1-piperidinecarboxylic acid ethyl ester (loratadine) | |
KR101134021B1 (ko) | 새로운 중간체를 이용하는 피타바스타틴 헤미칼슘의 신규한 제조방법 | |
CN117756801A (zh) | 一种非奈利酮的制备方法 | |
US6214847B1 (en) | Crystalline 10,10-Bis((2-fluoro-4-pyridinyl)methyl)-9(10H)-Anthracenone and an improved process for preparing the same | |
CN104098556A (zh) | 一种新的利伐沙班的合成工艺 | |
AU2002340487A1 (en) | Process for the preparation of 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)-cyclohepta-(1,2b)-pyridin-11-ylidene)-1-piperidinecarboxylic acid ethyl ester (loratadine) | |
MXPA06001485A (es) | Procedimiento para la preparacion de derivados de feniltetrazol. | |
CN107556237B (zh) | 一种3-(2-苯乙基)-2-吡啶甲酰胺类化合物的制备方法 | |
KR100856133B1 (ko) | 아토르바스타틴의 개선된 제조방법 | |
US5808082A (en) | Method of preparing phosphodiesterase IV inhibitors | |
US6084100A (en) | Process for the preparation of loratadine | |
WO2006022488A1 (en) | Process for purification of cilostazol | |
JPH09510981A (ja) | D−(+)−ビオチン中間体の改良された製造方法 | |
CN114524765A (zh) | 一种碱催化合成琥珀酸多西拉敏的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |